Cycle Pharma
The Barrett Building
Little St Mary’s Lane
Cambridge
CB2 1RR
United Kingdom
Tel: 44-0-1223-354118
Website: https://cyclepharma.com
Email: info@cyclepharma.com
About Cycle Pharma
Cycle Pharmaceuticals is committed to changing the way that HT-1 is treated and managed around the world. Cycle Pharmaceuticals has worked for more than four years closely with physicians and patient groups to reduce the impact that HT-1 treatment has on patients’ lives. Nityr is the first formulation of nitisinone treatment that does not require refrigeration (removing the need of a cold chain transportation and storage) and can be taken with or without food, representing a significant improvement from previous treatments for patients and caregivers.LEADERSHIP:
CEO: Antonio Benedetti
JOBS:
Please click here for Cycle Pharma job opportunities.
14 articles about Cycle Pharma
-
Cycle Pharmaceuticals launches SAJAZIRTM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)
9/28/2021
Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)
-
US FDA Grants Once Daily Dosing Option for NITYR (nitisinone) Tablets for HT-1 Patients
9/14/2020
Cycle Pharmaceuticals is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the once daily dosing of NITYR ® . This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200914005235/en/ (Photo: Business Wire) This dosing regimen is now an option for patients 5 years of age and older who have undetectable serum and urine succinylacetone co
-
Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020
9/8/2020
Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, has been featured as one of the Sunday Times 10 Tech Track Ones to Watch 2020.
-
Cycle Pharmaceuticals Secures $25 Million Debt Financing
9/7/2020
$25M Debt Facility from Deutsche Bank Accelerates Rare Disease Drug Pipeline - Building on Existing Profitable Rare Disease Drug Business
-
Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology
5/5/2020
Unique transdermal delivery technology and medicines for rare diseases combine to deliver significant quality-of-life benefits for patients
-
Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases Using Zydis ODT Technology
10/31/2019
Cycle Pharmaceuticals Ltd is pleased to announce that it has signed an agreement with Catalent, Inc., to develop innovative formulations targeting rare disease patients.
-
Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.
11/12/2018
NITYR™ is indicated for the treatment of patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
-
Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S.
8/29/2018
Ketorolac Tromethamine Tablets are a nonsteroidal anti-inflammatory drug
-
Aprecia and Cycle Partner to Develop 3D-Printed Orphan Drugs
12/12/2017
The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia's proprietary 3DP ZipDose Technology platform.
-
Cycle Pharmaceuticals Launches Free Trial of NITYR in the US and Partners With Cambrooke Therapeutics to Support HT-1 Patients’ Dietary Needs
11/13/2017
Cycle Pharmaceuticals launches of a new program in the US to offer patients with hereditary tyrosinemia type 1 (HT-1) the opportunity to experience NITYR (nitisinone) tablets for free for three weeks.
-
Cycle Pharma Receives FDA Approval And Launches Ketorolac Tromethamine Injection 30mg/ml In The U.S.
9/19/2017
-
Cycle Pharma Partners With Cardinal As The Logistic Provider For Nityr In U.S.
8/7/2017
-
Cycle Pharma Partners With Diplomat To Dispense Nityr In U.S.
8/3/2017
-
Cycle Pharma Receives FDA Approval Of Nityr (Nitisinone) Tablets For Treatment Of HT-1
8/1/2017